Bioregulators & Organ Support
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Anytime
Receptor / target
Cartilage
Properties
Not listed
Pre-mixed
No
Cartalax
← Back to Library
Protocol not independently verified Repair Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Cartalax is reviewed here for organ-support and bioregulator research.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Organ-support research, Tissue signaling
Mechanism
Target context: Cartilage
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Anytime
Receptor / target
Cartilage
Properties
Not listed
Pre-mixed
No
How Cartalax works in the body
Cartalax is a peptide bioregulator whose stated tissue target is cartilage.
Joint & cartilage (Bioregulator / limited data)
Researched for joint and cartilage tissue support. Evidence is limited and largely from bioregulator research.
Educational only, not medical advice. Labels describe the type of research behind each area, not a recommendation.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg 1x Daily | Take at bedtime fasted. Repeat 3-4 times per year. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1: Extended Protocol (Goal: deep cartilage matrix restoration for subjects with moderate-to-severe osteoarthritis; higher cumulative dose through extended lower-intensity daily exposure)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg 1x Daily at bedtime fasted | Higher-dose extended cycle. For significant osteoarthritis burden where maximal chondrocyte gene program normalization is the objective. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2: BPC-157 + TB-500 + Cartalax Joint Repair Triple Stack (Goal: comprehensive articular joint tissue restoration targeting chondrocyte gene programs (Cartalax), periarticular vasculature and tendon repair (BPC-157), and cytoskeletal repair mechanics (TB-500) simultaneously)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg Cartalax at bedtime fasted | Most complete joint repair protocol in the database. Cartalax at bedtime. 250mcg BPC-157 and 2mg TB-500 at their standard schedules (can be co-administered in morning injection). Assess joint pain VAS and ROM at day 0, day 20, and day 60. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 3: Athletes Joint Preservation Protocol (Goal: proactive articular cartilage maintenance for competitive athletes with high joint loading; quarterly cycling to stay ahead of cumulative mechanical cartilage stress)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 (quarterly) | 1mg 1x Daily at bedtime fasted | Proactive rather than reactive protocol. Begin before symptoms develop. Align with off-season training blocks where joint loading is lowest: this is when synovial fluid bioregulator diffusion is most effective without competing mechanical compression from heavy training. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 4: Post-Orthopedic Surgery Cartilage Rehabilitation Protocol (Goal: accelerate articular cartilage healing post-arthroscopy, microfracture surgery, or ACI procedure; minimum 6 weeks post-op, surgeon clearance required)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500mcg 1x Daily at bedtime fasted | Minimum 6 weeks post-surgical. Surgeon clearance required. Conservative entry during early weight-bearing rehabilitation. |
| Weeks 3-4 | 1mg 1x Daily at bedtime fasted | |
| Weeks 5-12 | 1mg 1x Daily at bedtime fasted | Extended recovery cycle. Add BPC-157 from week 3 for periarticular vascular and tendon support. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 5: Teriparatide + Cartalax Bone and Cartilage Joint Stack (Goal: simultaneous subchondral bone restoration (Teriparatide) and articular cartilage gene program normalization (Cartalax) for subjects with combined osteoarthritis and osteoporosis)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg Cartalax at bedtime fasted | 20mcg Teriparatide 1x Daily in the morning; Cartalax is dosed at bedtime fasted. This addresses both articular cartilage (Cartalax) and subchondral bone quality (Teriparatide) simultaneously. Mechanistically complementary: subchondral bone quality directly affects articular cartilage biomechanics. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older, regional, or weakly indexed evidence. Entry context: target (Cartilage); route Subcutaneous; timing Anytime. Unapproved or unverified dosing examples are hypotheses, not recommendations.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in organ-specific peptide-bioregulator literature, often with older regional clinical reports plus preclinical or mechanistic studies. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Cartilage. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Bioregulator entries commonly rely on organ-specific peptide literature with variable indexing and older clinical traditions.
- Treat organ-system claims cautiously unless they are supported by modern, indication-specific clinical trials or labels.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Days 1-20, 1mg 1x Daily; Alternative Titration 1: Extended Protocol (Goal: deep cartilage matrix restoration for subjects with moderate-to-severe osteoarthritis; higher cumulative dose through extended lower-intensity daily exposure): Days 1-20, 5mg 1x Daily at bedtime fasted.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor organ-specific labs, autoimmune/transplant context, cancer history, and the age/quality of the cited literature.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active septic arthritis: bioregulator chondrocyte activity during active bacterial joint infection is contraindicated; antimicrobial treatment and joint drainage are the priority.
- Active inflammatory arthritis in acute flare (rheumatoid arthritis, psoriatic arthritis, gout flare): the inflammatory milieu of acute arthritic flare creates a poor context for chondrocyte gene program normalization; Cartalax is a chronic bioregulator for non-inflammatory cartilage restoration.
- Chondrosarcoma or malignant bone/cartilage tumors: chondrocyte bioregulator activity in the context of malignant cartilage cells has not been evaluated.
- Known hypersensitivity to Cartalax (Ala-Glu-Asp tripeptide) or formulation excipients.
- Pregnancy: cartilage and connective tissue bioregulator effects during pregnancy have not been evaluated.
- Recent total joint arthroplasty: in subjects who have undergone total hip or knee replacement, the articular cartilage that Cartalax targets has been surgically removed; the bioregulator has no relevant target tissue in fully replaced joints.
- Concurrent high-dose systemic corticosteroids: corticosteroids suppress chondrocyte anabolic activity and inhibit proteoglycan synthesis through mechanisms that could counteract Cartalax's anabolic chondrocyte gene program normalization.
- Active biologic DMARD therapy for RA (tocilizumab, abatacept): the immunological context of active biologic DMARD use for RA represents an unpredictable environment for chondrocyte bioregulator activity; the cartilage is a target of ongoing autoimmune destruction that must be addressed at the inflammatory level first.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Mild transient joint discomfort: as chondrocyte metabolic activity increases and cartilage matrix remodeling begins, some subjects report mild transient joint ache in the first 3-5 days of a new cycle; reflects active cartilage bioregulator activity rather than damage; typically self-limiting.
- Mild increased joint warmth: uncommon; related to synovial fluid metabolic activity changes as chondrocyte and synoviocyte gene programs normalize; typically resolves within the first week.
- Injection site mild reaction: standard subcutaneous peptide response.
- Mild morning stiffness changes: as cartilage water content and proteoglycan composition normalize over the cycle, some subjects notice transient changes in morning joint stiffness duration; typically trending toward improvement over the cycle.
- No serious musculoskeletal adverse events documented in the Khavinson research literature: Cartalax's safety profile in osteoarthritis and aging joint tissue populations is clean at standard protocol doses.
- Unknown interaction with intra-articular corticosteroid or hyaluronic acid injections: subjects receiving concurrent intra-articular injections should coordinate timing with Cartalax cycles; no documented interactions exist but the local joint environment during active intra-articular injection therapy has not been specifically studied with concurrent Cartalax use.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.